Related Experiment Video

Updated: Aug 10, 2026

Analysis of Cell Cycle Position in Mammalian Cells
12:19

Analysis of Cell Cycle Position in Mammalian Cells

Published on: January 21, 2012

Dissection of CDK4-binding and transactivation activities of p34(SEI-1) and comparison between functions of

Junan Li1, Peter Muscarella, Sang Hoon Joo

  • 1Department of Surgery, College of Medicine, The Ohio State University, Columbus, Ohio 43210, USA. li.225@osu.edu

Biochemistry
|October 6, 2005
PubMed

Insights

SEI-1 regulates cell cycle progression through transactivation and CDK4 activation. Researchers identified key SEI-1 residues for these functions and found SEI-1 overexpressed in head and neck cancers, unlike p16.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Cancer Research

Background:

  • SEI-1 (also known as TRIP-Br1) is a protein involved in cell cycle regulation.
  • It possesses dual roles: transactivation of genes for G1/S transition and activation of cyclin-dependent kinase 4 (CDK4).

Purpose of the Study:

  • To dissect the dual roles of SEI-1 in cell cycle regulation.
  • To compare the functions of SEI-1 with those of p16.
  • To identify key residues in SEI-1 responsible for its transactivation and CDK4 binding activities.

Main Methods:

  • Yeast one-hybrid and site-directed mutagenesis to identify critical SEI-1 residues for transactivation.
  • Yeast two-hybrid analysis to assess SEI-1 binding and activation of CDK4 using transactivation-negative mutants.
  • Analysis of site-specific CDK4 mutants to compare binding affinities with SEI-1, p16, and cyclin D2.
  • Expression level comparison of SEI-1 and p16 in human squamous cell carcinomas of the head and neck.

Main Results:

  • Specific SEI-1 residues within the heptad repeat and C-terminal segments were identified as crucial for transactivation.
  • Transactivation mediated by the heptad repeat is distinct from acidic region-mediated transactivation.
  • Certain SEI-1 mutants lacking transactivation ability retained full capacity to bind and activate CDK4.
  • Differences were observed in the binding of SEI-1, p16, and cyclin D2 to CDK4.
  • SEI-1 was consistently overexpressed, while p16 was consistently underexpressed in head and neck squamous cell carcinomas.

Conclusions:

  • SEI-1 exhibits distinct functional domains for transactivation and CDK4 activation.
  • The study elucidates the molecular mechanisms underlying SEI-1's functions and its differential expression compared to p16 in cancer.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...